Vanda Pharmaceuticals Inc. (VNDA) on Wednesday said the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), a rare autoinflammatory skin disorder.
A decision from the regulator is expected on December 12, 2026.
In the pivotal efficacy studies GEMINI-1 and GEMINI-2, a single intravenous dose of imsidolimab produced rapid disease clearance, with 53% of patients achieving clear or almost clear skin by Week 4, compared with 13% on placebo. Efficacy was sustained over approximately 2 years of monthly maintenance dosing, with no flares reported in the treatment arm. Imsidolimab demonstrated a favorable safety profile and a low incidence of anti-drug antibodies.
Vanda Pharmaceuticals shares closed at $8.17 on Tuesday, up 0.25%.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.